Expleo Solutions Balance Sheet Health
Financial Health criteria checks 5/6
Expleo Solutions has a total shareholder equity of ₹5.6B and total debt of ₹245.7M, which brings its debt-to-equity ratio to 4.4%. Its total assets and total liabilities are ₹7.3B and ₹1.7B respectively. Expleo Solutions's EBIT is ₹1.2B making its interest coverage ratio -70.3. It has cash and short-term investments of ₹1.3B.
Key information
4.4%
Debt to equity ratio
₹245.69m
Debt
| Interest coverage ratio | -70.3x |
| Cash | ₹1.29b |
| Equity | ₹5.63b |
| Total liabilities | ₹1.68b |
| Total assets | ₹7.31b |
Recent financial health updates
No updates
Recent updates
When Should You Buy Expleo Solutions Limited (NSE:EXPLEOSOL)?
Jun 21
Investors Could Be Concerned With Expleo Solutions' (NSE:EXPLEOSOL) Returns On Capital
Mar 15The Returns On Capital At Expleo Solutions (NSE:EXPLEOSOL) Don't Inspire Confidence
Sep 15Increases to Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Might Cool off for now
Aug 19Calculating The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Jul 14Many Would Be Envious Of Expleo Solutions' (NSE:EXPLEOSOL) Excellent Returns On Capital
May 05A Look At The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Mar 15Expleo Solutions Limited's (NSE:EXPLEOSOL) Stock Been Rising: Are Strong Financials Guiding The Market?
Feb 15
Expleo Solutions (NSE:EXPLEOSOL) Knows How to Allocate Capital
Jan 24Introducing Expleo Solutions (NSE:EXPLEOSOL), A Stock That Climbed 76% In The Last Year
Jan 04A Look At The Intrinsic Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Dec 14Is There More To The Story Than Expleo Solutions's (NSE:EXPLEOSOL) Earnings Growth?
Nov 26Financial Position Analysis
Short Term Liabilities: EXPLEOSOL's short term assets (₹5.6B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: EXPLEOSOL's short term assets (₹5.6B) exceed its long term liabilities (₹312.9M).
Debt to Equity History and Analysis
Debt Level: EXPLEOSOL has more cash than its total debt.
Reducing Debt: EXPLEOSOL's debt to equity ratio has increased from 0% to 4.4% over the past 5 years.
Debt Coverage: EXPLEOSOL's debt is well covered by operating cash flow (154.9%).
Interest Coverage: EXPLEOSOL earns more interest than it pays, so coverage of interest payments is not a concern.